Liminatus Pharma Appeals Nasdaq Delisting Notice, Suspension Stayed
LIMN sits 44% above its 52-week low of $0.132.
Summary
Liminatus Pharma received a formal Nasdaq delisting notice on May 20th for failing to meet minimum value requirements. This follows a prior news report on May 22nd about the delisting notification. The company has appealed the decision on May 26th, which temporarily stays any suspension or delisting action pending a hearing. This development provides a temporary reprieve for the company, which has recently reported significant net losses and expressed substantial doubt about its ability to continue as a going concern in its Q1 2026 10-Q filing. The outcome of the appeal hearing will be critical for the company's future listing status.
At the time of this announcement, LIMN was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.13 to $33.66. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.